Glycomine is committed to developing therapeutics for serious rare diseases, the vast majority of which do not have any disease-modifying treatment options available. There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. Even though the number of patients affected by any single disease may total several hundred or thousand, it is estimated the total number of people affected by all such diseases is more than 20 million in the U.S. alone.

Our team has a special dedication to find solutions to the significant unmet medical need experienced by patients and families with rare diseases. We come from many disciplines and bring multiple viewpoints and broad expertise to our mission. We are driven by the imperative and the opportunity to develop therapies that can provide meaningful improvements in the quality of life for patients, caregivers, and families.